Detailed information for compound 66801

Basic information

Technical information
  • TDR Targets ID: 66801
  • Name: [6-ethynyl-2-(4-hydroxyphenyl)-1-benzothiophe n-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]met hanone
  • MW: 481.605 | Formula: C30H27NO3S
  • H donors: 1 H acceptors: 2 LogP: 6.69 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: C#Cc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O
  • InChi: 1S/C30H27NO3S/c1-2-21-6-15-26-27(20-21)35-30(23-7-11-24(32)12-8-23)28(26)29(33)22-9-13-25(14-10-22)34-19-18-31-16-4-3-5-17-31/h1,6-15,20,32H,3-5,16-19H2
  • InChiKey: RYTPYECEXOQEHM-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • [6-ethynyl-2-(4-hydroxyphenyl)benzothiophen-3-yl]-[4-[2-(1-piperidyl)ethoxy]phenyl]methanone
  • [6-ethynyl-2-(4-hydroxyphenyl)-3-benzothiophenyl]-[4-[2-(1-piperidyl)ethoxy]phenyl]methanone
  • [6-ethynyl-2-(4-hydroxyphenyl)benzothiophen-3-yl]-[4-(2-piperidinoethoxy)phenyl]methanone

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens estrogen receptor 2 (ER beta) References
Homo sapiens estrogen receptor 1 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Loa Loa (eye worm) hypothetical protein estrogen receptor 2 (ER beta) 495 aa 418 aa 25.8 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Onchocerca volvulus 0.0021 0 0.5
Loa Loa (eye worm) acetylcholinesterase 1 0.0126 1 1
Echinococcus multilocularis acetylcholinesterase 0.0126 1 1
Echinococcus granulosus acetylcholinesterase 0.0126 1 1
Mycobacterium tuberculosis POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) 0.0021 0 0.5
Schistosoma mansoni family S9 non-peptidase homologue (S09 family) 0.0126 1 1
Mycobacterium tuberculosis POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) 0.0021 0 0.5
Onchocerca volvulus 0.0021 0 0.5
Onchocerca volvulus 0.0021 0 0.5
Onchocerca volvulus 0.0021 0 0.5
Echinococcus multilocularis carboxylesterase 5A 0.0126 1 1
Mycobacterium tuberculosis Carboxylesterase LipT 0.0021 0 0.5
Loa Loa (eye worm) hypothetical protein 0.0126 1 1
Loa Loa (eye worm) hypothetical protein 0.0126 1 1
Echinococcus granulosus carboxylesterase 5A 0.0126 1 1
Brugia malayi Carboxylesterase family protein 0.0126 1 1
Loa Loa (eye worm) carboxylesterase 0.0126 1 1
Onchocerca volvulus 0.0021 0 0.5
Mycobacterium ulcerans carboxylesterase, LipT 0.0021 0 0.5
Trichomonas vaginalis spcc417.12 protein, putative 0.0021 0 0.5
Echinococcus granulosus acetylcholinesterase 0.0126 1 1
Echinococcus multilocularis acetylcholinesterase 0.0126 1 1
Trichomonas vaginalis carboxylesterase domain containing protein, putative 0.0021 0 0.5

Activities

Activity type Activity value Assay description Source Reference
Decrease (functional) = 39.4 % Percent decrease in serum cholesterol relative to OVX control at 0.1 mg/kg in rat was determined (in vivo) ChEMBL. 9003514
Decrease (functional) = 58.7 % Percent decrease in serum cholesterol relative to OVX control at 1 mg/kg in rat ChEMBL. 9003514
Decrease (functional) = 65.8 % Percent decrease in serum cholesterol relative to OVX control at 10 mg/kg in rat was determined (in vivo) ChEMBL. 9003514
ED50 (functional) = 0.5 mg kg-1 Dose required to reduce serum cholesterol by 50% relative to OVX controls was determined (in vivo) ChEMBL. 9003514
IC50 (functional) = 20 nM Antagonist effect in breast tissue was assayed by inhibition of estrogen stimulated MCF-7 cell proliferation ChEMBL. No reference
IC50 (functional) = 20 nM Antagonism of estrogen action in a mammary tumor cell line was assayed via inhibition of MCF-7 cell proliferation stimulated by 10 e-11 M 17-beta-estradiol (in vitro) ChEMBL. 9003514
IC50 (functional) = 20 nM Antagonist effect in breast tissue was assayed by inhibition of estrogen stimulated MCF-7 cell proliferation ChEMBL. No reference
IC50 (functional) = 20 nM Antagonism of estrogen action in a mammary tumor cell line was assayed via inhibition of MCF-7 cell proliferation stimulated by 10 e-11 M 17-beta-estradiol (in vitro) ChEMBL. 9003514
Increase (functional) = 27.8 % Minimum effective dose at which significant increase in uterine weight/body weight in rat was determined (in vivo); expressed as % increase relative to ovariectomized (OVX) controls ChEMBL. 9003514
MED (functional) = 1 mg kg-1 Minimum effective dose at which significant increase in uterine weight/body weight in rat was determined (in vivo) ChEMBL. 9003514
MED (functional) > 10 mg kg-1 Minimum effective dose at which significant increase in uterine eosinophil peroxidase (EPO) activity in rat was determined (in vivo) ChEMBL. 9003514
RBA (binding) = 0.029 In vitro relative binding affinity by competition with [3H]-17-beta-estradiol for estrogen receptor in MCF-7 cell lysate ChEMBL. 9003514
RBA (binding) = 0.029 In vitro relative binding affinity by competition with [3H]-17-beta-estradiol for estrogen receptor in MCF-7 cell lysate ChEMBL. 9003514
Relative binding affinity (binding) = 0.029 Affinity against estrogen receptor in MCF-7 cell lysate by competitive displacement of [3H]-Estradiol ChEMBL. No reference
Relative binding affinity (binding) = 0.029 Affinity against estrogen receptor in MCF-7 cell lysate by competitive displacement of [3H]-Estradiol ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.